drugset / Trial / NCT00649077
Fasting Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg
RandomizedCrossoverOpen-labelOther
Summary
The objective of this study was to investigate the bioequivalence of Mylan's meloxicam 15 mg tablets and Boehringer Ingelheim's Mobic® 15 mg tablets following a single, oral 15 mg (1 x 15 mg) dose administration under fasting conditions.
Timeline
- Start
- 2004-08
- Primary completion
- 2004-09
- Completion
- 2004-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Meloxicam | Small molecule | 15 mg | Oral |
Indications
No indication recorded.